Vetter, a global CDMO, has further invested in additional capacity to meet the growing global demand for clinical manufacturing for injectable drug products.
 
The company purchased a clinical manufacturing location in Rankweil, Austria, a year ago and the site has been modified to quality standards in aseptic fill and finish for drug-delivery systems. “With this additional facility we will further expand our capability for early clinical development for phase I and phase II drug candidates,” said Vetter Managing Director Peter Soelkner. “The dedicated manufacturing site will focus on supporting our customers on quality, timeliness and technical expertise.”
 
The production site currently offers 100,000 sq.-ft. of offices, lab space, areas for material preparation as well as room temperature, cool and frozen storage and one automated vial filling line for liquid and lyophilized products. “Through various measures and modifications, all systems and manufacturing processes have been successfully integrated into our business operations and the site is now ready for operations,” said Vetter Managing Director Thomas Otto. “The site also offers opportunities for possible future expansion.”
 
In the coming months, media fills for different vial formats will be performed onsite that simulate the actual drug manufacturing process and represent an important step in preparing for future customers projects. The next milestone for the new clinical site will be the official GMP inspection for obtaining the manufacturing license in the beginning of 4Q21. The authority responsible for this site is the Austrian BASG/AGES (Federal Office for Safety in Health Care/Agency for Health and Food Safety).